Valuation: Aura Biosciences, Inc.

Market Cap 625M 558M 512M 466M 874M 59.2B 891M 6.12B 2.47B 31.25B 2.35B 2.3B 98.7B P/E 2026 *
-3.62x
P/E 2027 * -3.97x
Enterprise Value 625M 558M 512M 466M 874M 59.2B 891M 6.12B 2.47B 31.25B 2.35B 2.3B 98.7B EV / Sales 2026 *
-
EV / Sales 2027 * 127x
Free-Float
91.46%
Yield 2026 *
-
Yield 2027 * -
1 day-1.79%
1 week-2.43%
Current month-1.79%
1 month-0.99%
3 months-13.98%
6 months-13.98%
Current year+10.64%
1 week 5.88
Extreme 5.88
6.51
1 month 5.88
Extreme 5.88
6.77
Current year 4.73
Extreme 4.73
9.54
1 year 4.73
Extreme 4.73
9.54
3 years 4.34
Extreme 4.345
12.38
5 years 4.34
Extreme 4.345
26.16
10 years 4.34
Extreme 4.345
26.16
Manager TitleAgeSince
Chief Executive Officer 53 2026-04-29
Director of Finance/CFO 53 2026-09-01
Chief Operating Officer 52 2026-08-09
Director TitleAgeSince
Director/Board Member 41 2019-03-31
Chairman 61 2020-12-31
Director/Board Member 55 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

70,000 0.0675%
9/1/26 Free

Chief Operating Officer

400,000 0.3857%
9/1/26 Free

Chief Technology Officer

175,000 0.1687%
Change 5-day change 1-year change 3-year change Capi.($)
-1.79%-2.43%-1.63%-41.57% 625M
-2.37%-5.03%+39.49%+62.39% 62.23B
-2.87%+0.49%+11.11%+69.18% 54.92B
+0.62%+2.11%+16.96%+102.56% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
-5.47%+24.76%+101.20%+87.34% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -2.20%+3.60%+39.51%+158.78% 38.67B
Weighted average by Cap. -2.13%+2.74%+44.44%+163.53%

Financials

2026 *2027 *
Net sales - 4.92M 4.4M 4.03M 3.67M 6.88M 466M 7.02M 48.19M 19.43M 246M 18.48M 18.09M 777M
Net income -154M -137M -126M -115M -215M -14.56B -219M -1.51B -607M -7.69B -577M -565M -24.28B -167M -149M -137M -124M -233M -15.81B -238M -1.63B -659M -8.35B -627M -614M -26.36B
Net Debt - -
Projected Income Statement - Annual - Aura Biosciences, Inc.
Logo Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Employees
113
Date Price Change Volume
26-11-02 US$6.030 -1.79% 746,584
26-10-30 US$6.140 -2.46% 533,014
26-10-29 US$6.295 -1.64% 769,976
26-10-28 US$6.400 +1.59% 541,883
26-10-27 US$6.300 +1.94% 680,261
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aura Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.030USD
Average target price
16.60USD
Spread / Average Target
+175.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aura Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. AURA Stock